Travere TherapeuticsTVTX
About: Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Employees: 380
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
51% more capital invested
Capital invested by funds: $765M [Q2] → $1.16B (+$392M) [Q3]
50% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]
16% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 25
2% more funds holding
Funds holding: 172 [Q2] → 176 (+4) [Q3]
9% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 57
12.12% less ownership
Funds ownership: 120.21% [Q2] → 108.08% (-12.12%) [Q3]
17% less call options, than puts
Call options by funds: $12.4M | Put options by funds: $14.9M
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
11 analyst ratings
Piper Sandler Allison Bratzel 82% 1-year accuracy 9 / 11 met price target | 28%upside $22 | Neutral Maintained | 14 Nov 2024 |
Scotiabank Greg Harrison 33% 1-year accuracy 9 / 27 met price target | 58%upside $27 | Sector Outperform Maintained | 1 Nov 2024 |
Barclays Carter Gould 29% 1-year accuracy 11 / 38 met price target | 17%upside $20 | Overweight Maintained | 1 Nov 2024 |
Wells Fargo Mohit Bansal 24% 1-year accuracy 6 / 25 met price target | 58%upside $27 | Overweight Upgraded | 21 Oct 2024 |
Leerink Partners Joseph Schwartz 25% 1-year accuracy 2 / 8 met price target | 134%upside $40 | Outperform Maintained | 11 Oct 2024 |
Financial journalist opinion
Based on 5 articles about TVTX published over the past 30 days